Later research showed that PRMT3 mediates metabolic reprogramming and cell proliferation by methylating the R248 site on the glycolytic enzyme GAPDH, indicating that dual blockade of GAPDH and mitochondrial respiration might offer a new approach to treat pancreatic cancer with overexpression of PRMT3 [70]. Here, GAPDH is linked to pancreatic neoplasm.